The growth of biologics (including drugs like mAbs, GLP-1, RNA-based drugs, and vaccines) is driving the need for new solutions in terms of primary containers, delivery devices, and technologies to rise to the challenge of critical issues such as protein aggregation, inorganic extractables, underdosing, and delamination.  

That’s why Stevanato Group has developed the Alba® pre-filled syringe platform for high-value drugs. It significantly reduces development time, time to market, and the quality costs associated with any wastage of the drug product. Alba® is a breakthrough solution for silicone challenges, achieving minimized particle release and optimal drug product stability. Another rapidly growing area in the healthcare industry is GLP-1 drugs, which are transforming the treatment of diabetes and obesity. A reliable container supply, smooth operation, and safe and easy self-administration are crucial for these new drugs, so Stevanato Group has developed the Nexa® high-performance syringe system. Nexa® syringes are optimized for integration in auto-injectors and give consistent gliding and injection force, with ultra-low tungsten and glue residuals, and enhanced cosmetic quality. 

Stevanato Group is also constantly investing in its portfolio of injection devices to meet the evolving needs of patients and pharma companies. Each patient therapy requires a unique solution, and that’s why the company has three very different products in its portfolio – the Alina® pen injector, the Aidaptus® auto-injector, and the Vertiva® on-body delivery system platform. Stevanato Group also provides contract manufacturing organization (CMO) services to pharma companies to support injection device projects. Its unique approach as a one-stop-shop provider means it can cover the entire product lifecycle, from concept definition to industrial delivery and final packaging – for faster time to market and reduced total cost of ownership. 

Moreover, Stevanato Group recently created a new hub of excellence in Fishers, Indiana, positioned to meet U.S. market needs. The new hub in Indiana will host, amongst others, the production of drug containment solutions, including the EZ-fill® pre-sterilized platform, device manufacturing, and an after-sales support center for equipment. 

Come and visit Stevanato Group at DCAT Week 2025 at The Fifty Sonesta Select New York! 

Home – Managing Complexity, Delivering Value – Stevanato Group